PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:PTCT
- CUSIP: N/A
- Web: www.ptcbio.com
Capitalization:- Market Cap: $739.51 million
- Outstanding Shares: 34,316,000
Average Prices:- 50 Day Moving Avg: $17.62
- 200 Day Moving Avg: $13.41
- 52 Week Range: $4.03 - $21.62
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.05
- P/E Growth: 0.61
Sales & Book Value:- Annual Revenue: $90.36 million
- Price / Sales: 8.18
- Book Value: $2.94 per share
- Price / Book: 7.33
Profitability:- EBIDTA: ($114,520,000.00)
- Net Margins: -143.80%
- Return on Equity: -98.77%
- Return on Assets: -46.75%
Debt:- Debt-to-Equity Ratio: 0.99%
- Current Ratio: 5.30%
- Quick Ratio: 5.27%
Misc:- Average Volume: 806,476 shs.
- Beta: 1.36
- Short Ratio: 7.47
Frequently Asked Questions for PTC Therapeutics (NASDAQ:PTCT)
What is PTC Therapeutics' stock symbol?
PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."
How were PTC Therapeutics' earnings last quarter?
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Monday, May, 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.88) by $0.03. The company had revenue of $26.50 million for the quarter, compared to analyst estimates of $27.93 million. PTC Therapeutics had a negative return on equity of 98.77% and a negative net margin of 143.80%. PTC Therapeutics's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.22) earnings per share. View PTC Therapeutics' Earnings History.
Where is PTC Therapeutics' stock going? Where will PTC Therapeutics' stock price be in 2017?
9 equities research analysts have issued 12-month target prices for PTC Therapeutics' stock. Their predictions range from $7.00 to $25.00. On average, they expect PTC Therapeutics' stock price to reach $15.25 in the next year. View Analyst Ratings for PTC Therapeutics.
What are analysts saying about PTC Therapeutics stock?
Here are some recent quotes from research analysts about PTC Therapeutics stock:
- 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (7/11/2017)
- 2. Cowen and Company analysts commented, "PTCT announced 4Q16 results today: Translarna EU sales continue to grow." (3/16/2017)
- 3. Royal Bank Of Canada analysts commented, "PTCT has announced it has filed its NDA for ataluren with FDA under protest and that the filing has been acknowledged: Recall that the FDA issued a Refuse-to-File letter on 2/23/16. The NDA was initially filed on 1/8/16 and was based on the results of the confirmatory Phase III ACTDMD trial, released 10/15/15, which failed to meet its primary endpoint. We continue to see very little chance that ataluren gets approved in the US, given compelling evidence from multiple randomized clinical trials where this compound failed to meet its primary endpoint. We believe that despite what looks like an improving/lower-threshold FDA environment, the only way this compound can get approval is if it succeeds in a new Phase III trial. Absent that, we believe that the key opportunity to evaluate in PTCT shares are Translarna ex-US sales, which we view as fully valued at current levels. We reiterate our Sector Perform rating on PTCT." (3/6/2017)
- 4. Jefferies Group LLC analysts commented, "PTCT reported ~$81M Translarna net sales in 2016 (higher vs. our est of $75M) and guided $105-125M for 2017 sales. The topline data for Translarna Ph3 study in CF continues to be expected in late-1Q17 and the company plans to file NDA in DMD over protest in the US. Additional pipeline in SMA and cancer are progressing on-track." (1/10/2017)
Who are some of PTC Therapeutics' key competitors?
Some companies that are related to PTC Therapeutics include Array BioPharma (ARRY), Acceleron Pharma (XLRN), Dermira (DERM), Xencor (XNCR), Amarin Corporation PLC (AMRN), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Acorda Therapeutics (ACOR), Neuroderm Ltd (NDRM), Omeros Corporation (OMER), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Ascendis Pharma A/S (ASND), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), Reata Pharmaceuticals (RETA) and Aclaris Therapeutics (ACRS).
Who are PTC Therapeutics' key executives?
PTC Therapeutics' management team includes the folowing people:
- Michael Schmertzler, Independent Chairman of the Board
- Stuart W. Peltz Ph.D., Chief Executive Officer, Director
- Christine Utter, Principal Financial Officer, Principal Accounting Officer, Treasurer
- Marcio Souza, Chief Operating Officer
- Neil Almstead Ph.D., Executive Vice President, Research, PharmaceuticalOperations & Technology
- Mark E. Boulding, Executive Vice President, Chief Legal Officer
- Tuyen Ong, Chief Medical Officer
- Mark A. Rothera, Chief Commercial Officer
- Glenn D. Steele Jr., M.D., Ph.D., Director
- Dawn Svoronos, Director
Who owns PTC Therapeutics stock?
PTC Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.26%), Bank of Montreal Can (0.08%), Nisa Investment Advisors LLC (0.03%) and Creative Planning (0.03%). Company insiders that own PTC Therapeutics stock include Dawn Svoronos, Mark Rothera and Neil Gregory Almstead. View Institutional Ownership Trends for PTC Therapeutics.
Who sold PTC Therapeutics stock? Who is selling PTC Therapeutics stock?
Who bought PTC Therapeutics stock? Who is buying PTC Therapeutics stock?
PTC Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have bought PTC Therapeutics stock in the last two years include Dawn Svoronos and Mark Rothera. View Insider Buying and Selling for PTC Therapeutics.
How do I buy PTC Therapeutics stock?
Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PTC Therapeutics' stock price today?
One share of PTC Therapeutics stock can currently be purchased for approximately $21.55.
MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for PTC Therapeutics (NASDAQ:PTCT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.22) |
| Consensus Price Target: | $15.25 (29.23% downside) |
Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/20/2017 | Citigroup Inc. | Reiterated Rating | Buy | $28.00 -> $17.00 | High |  |
| 6/30/2017 | J P Morgan Chase & Co | Reiterated Rating | Neutral | $15.00 -> $21.00 | Low | |
| 5/8/2017 | Royal Bank Of Canada | Set Price Target | Hold | $12.00 | High | |
| 3/22/2017 | Barclays PLC | Reiterated Rating | Equal Weight | $13.00 | Medium | |
| 3/16/2017 | Cowen and Company | Reiterated Rating | Hold | | High | |
| 3/6/2017 | Credit Suisse Group | Reiterated Rating | Outperform -> Positive | $25.00 | N/A | |
| 1/10/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $12.00 | N/A | |
| 11/11/2016 | Wedbush | Reiterated Rating | Neutral | $12.00 -> $7.00 | N/A | |
| 10/3/2016 | Bank of America Corporation | Reiterated Rating | Hold | $15.00 | N/A | |
| 4/17/2016 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | $39.00 | N/A | |
| 10/16/2015 | Roth Capital | Reiterated Rating | Hold | $63.00 | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for PTC Therapeutics (NASDAQ:PTCT)Earnings History by Quarter for PTC Therapeutics (NASDAQ PTCT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q1 2017 | ($0.88) | ($0.85) | $27.93 million | $26.50 million | View | Listen | |
| 3/16/2017 | 12/31/2016 | ($1.07) | ($0.78) | $24.69 million | $25.20 million | View | N/A | |
| 11/2/2016 | Q316 | ($1.22) | ($1.03) | $19.76 million | $23.00 million | View | N/A | |
| 8/4/2016 | Q216 | ($1.27) | ($1.14) | $15.24 million | $15.40 million | View | N/A | |
| 5/5/2016 | Q116 | ($1.26) | ($1.22) | $13.74 million | $18.90 million | View | N/A | |
| 2/29/2016 | Q415 | ($1.25) | ($1.50) | $13.04 million | $12.70 million | View | Listen | |
| 11/9/2015 | Q315 | ($1.15) | ($1.27) | $9.88 million | $9.78 million | View | Listen | |
| 7/30/2015 | Q215 | ($1.20) | ($1.14) | $7.73 million | $6.77 million | View | Listen | |
| 5/4/2015 | Q115 | ($1.20) | ($1.15) | $2.97 million | $7.50 million | View | N/A | |
| 2/27/2015 | Q414 | ($0.83) | ($0.84) | $7.99 million | $12.70 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.90) | ($0.93) | $1.76 million | $1.69 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.75) | ($0.86) | $1.71 million | $1.70 million | View | N/A | |
| 5/6/2014 | | ($0.46) | ($0.58) | $10.93 million | $9.22 million | View | N/A | |
| 3/6/2014 | Q413 | ($0.57) | ($0.75) | $6.15 million | $4.40 million | View | N/A | |
| 11/14/2013 | Q3 | ($0.29) | ($0.19) | $7.20 million | $16.29 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for PTC Therapeutics (NASDAQ:PTCT)2017 EPS Consensus Estimate: ($2.93)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.96) | ($0.70) | ($0.83) |
| Q2 2017 | 2 | ($0.93) | ($0.38) | ($0.66) |
| Q3 2017 | 2 | ($0.89) | ($0.32) | ($0.61) |
| Q4 2017 | 2 | ($0.88) | ($0.80) | ($0.84) |
(Data provided by Zacks Investment Research)
Dividend History for PTC Therapeutics (NASDAQ:PTCT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for PTC Therapeutics (NASDAQ:PTCT)Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 76.43%
Insider Trades by Quarter for PTC Therapeutics (NASDAQ:PTCT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/23/2017 | Dawn Svoronos | Director | Buy | 25,000 | $13.49 | $337,250.00 | |
| 1/5/2017 | Neil Gregory Almstead | EVP | Sell | 78 | $11.82 | $921.96 | |
| 3/3/2016 | Mark Rothera | Insider | Buy | 2,000 | $6.23 | $12,460.00 | |
| 7/6/2015 | David P Southwell | Director | Sell | 23,604 | $47.52 | $1,121,662.08 | |
| 6/18/2015 | Allan Steven Jacobson | Director | Sell | 5,000 | $50.13 | $250,650.00 | |
| 6/9/2015 | Stuart Walter Peltz | CEO | Sell | 100,000 | $54.49 | $5,449,000.00 | |
| 6/8/2015 | Mark Elliott Boulding | VP | Sell | 56,849 | $55.04 | $3,128,968.96 | |
| 6/8/2015 | Richard Aldrich | Director | Sell | 7,000 | $55.66 | $389,620.00 | |
| 6/8/2015 | Stuart Walter Peltz | CEO | Sell | 73,700 | $54.91 | $4,046,867.00 | |
| 5/22/2015 | Shane William Charles Kovacs | CFO | Sell | 82,491 | $55.41 | $4,570,826.31 | |
| 4/15/2015 | Neil Gregory Almstead | EVP | Sell | 9,511 | $68.65 | $652,930.15 | |
| 3/23/2015 | David P Southwell | Director | Sell | 2,317 | $69.04 | $159,965.68 | |
| 3/23/2015 | Stuart Walter Peltz | CEO | Sell | 47,200 | $69.14 | $3,263,408.00 | |
| 3/20/2015 | Mark Elliott Boulding | VP | Sell | 21,142 | $68.12 | $1,440,193.04 | |
| 3/18/2015 | Allan Steven Jacobson | Director | Sell | 16,616 | $76.00 | $1,262,816.00 | |
| 3/17/2015 | Mark Rothera | Insider | Sell | 10,700 | $76.64 | $820,048.00 | |
| 3/16/2015 | Michael L Kranda | Director | Sell | 2,500 | $72.81 | $182,025.00 | |
| 3/13/2015 | Robert J Spiegel | Insider | Sell | 1,030 | $75.10 | $77,353.00 | |
| 3/10/2015 | Neil Gregory Almstead | EVP | Sell | 79 | $70.71 | $5,586.09 | |
| 3/9/2015 | Stuart Walter Peltz | CEO | Sell | 47,201 | $70.74 | $3,338,998.74 | |
| 2/25/2015 | Mark Rothera | Insider | Sell | 35,000 | $68.01 | $2,380,350.00 | |
| 2/24/2015 | Mark Rothera | Insider | Sell | 1,000 | $67.70 | $67,700.00 | |
| 2/23/2015 | Mark Rothera | Insider | Sell | 23,000 | $65.40 | $1,504,200.00 | |
| 1/21/2015 | Neil Gregory Almstead | EVP | Sell | 26,096 | $60.26 | $1,572,544.96 | |
| 1/20/2015 | Mark Rothera | Insider | Sell | 3,000 | $60.02 | $180,060.00 | |
| 1/16/2015 | Mark Rothera | Insider | Sell | 2,300 | $58.67 | $134,941.00 | |
| 1/15/2015 | Claudia De Oliveira Ri Hirawat | President | Sell | 2,149 | $57.19 | $122,901.31 | |
| 1/14/2015 | Mark Rothera | Insider | Sell | 9,700 | $58.04 | $562,988.00 | |
| 12/15/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 2,173 | $55.24 | $120,036.52 | |
| 11/17/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 2,173 | $39.78 | $86,441.94 | |
| 10/15/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 45,661 | $36.15 | $1,650,645.15 | |
| 10/10/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 43,489 | $36.18 | $1,573,432.02 | |
| 10/1/2014 | Stuart Walter Peltz | CEO | Sell | 41,501 | $42.65 | $1,770,017.65 | |
| 9/26/2014 | Mark Rothera | Insider | Sell | 16,000 | $44.63 | $714,080.00 | |
| 9/18/2014 | Allan Steven Jacobson | Director | Sell | 2,000 | $40.16 | $80,320.00 | |
| 9/15/2014 | Mark Rothera | Insider | Sell | 8,000 | $36.24 | $289,920.00 | |
| 5/22/2014 | Shane William Charles Kovacs | CFO | Sell | 1,650 | $14.74 | $24,321.00 | |
| 3/24/2014 | Stuart Walter Peltz | CEO | Sell | 25,487 | $29.86 | $761,041.82 | |
| 3/21/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 15,320 | $29.61 | $453,625.20 | |
| 3/21/2014 | David Southwell | Director | Sell | 2,317 | $30.93 | $71,664.81 | |
| 3/20/2014 | Mark Elliott Boulding | VP | Sell | 10,049 | $30.96 | $311,117.04 | |
| 3/19/2014 | Neil Gregory Almstead | VP | Sell | 10,859 | $31.91 | $346,510.69 | |
| 3/18/2014 | Allan Steven Jacobson | Director | Sell | 7,616 | $31.18 | $237,466.88 | |
| 3/14/2014 | Michael Kranda | Director | Sell | 1,186 | $31.02 | $36,789.72 | |
| 3/13/2014 | Robert Spiegel | Insider | Sell | 1,186 | $31.75 | $37,655.50 | |
| 3/7/2014 | Stuart Walter Peltz | CEO | Sell | 27,414 | $29.91 | $819,952.74 | |
| 12/17/2013 | Hbm Healthcare Investments (Ca | major shareholder | Sell | 66,667 | $19.08 | $1,272,006.36 | |
| 6/25/2013 | Adam Koppel | Director | Buy | 1,250,000 | $15.00 | $18,750,000.00 | |
| 6/25/2013 | Hbm Healthcare Investments (Ca | Major Shareholder | Buy | 666,676 | $15.00 | $10,000,140.00 | |
| 6/25/2013 | Mark Rothera | Insider | Buy | 25,000 | $15.00 | $375,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for PTC Therapeutics (NASDAQ:PTCT)
Latest Headlines for PTC Therapeutics (NASDAQ:PTCT)
| Source: |
|
| Date | Headline |
|---|
 | PTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development
finance.yahoo.com - July 24 at 4:34 PM |
 | PTC Therapeutics, Inc. (NASDAQ:PTCT) Rating Reiterated by Citigroup Inc.
www.americanbankingnews.com - July 20 at 10:35 AM |
 | PTC Therapeutics (PTCT) Releases Results from ACT DMD in The ... - StreetInsider.com
www.streetinsider.com - July 20 at 6:40 AM |
| Zacks: Brokerages Expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to Announce -$0.97 Earnings Per Share
www.americanbankingnews.com - July 19 at 11:34 AM |
| PTC Therapeutics (PTCT) Releases Results from ACT DMD in The Lancet
www.streetinsider.com - July 19 at 5:31 AM |
| PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet
finance.yahoo.com - July 19 at 5:31 AM |
| How These Biotechs Are Dodging Payor Pushback In Muscular Dystrophy
finance.yahoo.com - July 18 at 7:33 AM |
| PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 14 at 10:52 PM |
| Here's Why PTC Therapeutics, Inc. Popped 45.2% in June
finance.yahoo.com - July 8 at 1:46 PM |
 | Here's Why PTC Therapeutics, Inc. Popped 45.2% in June
www.fool.com - July 8 at 7:00 AM |
| PTC Therapeutics (PTCT) Presents Phase 2 SUNFISH Trial Evaluating Oral RG7916 from Spinal Muscular Atrophy ... - StreetInsider.com
www.streetinsider.com - July 4 at 6:38 AM |
| Preliminary Phase 2 Data from Spinal Muscular Atrophy Program Presented at CureSMA Conference
finance.yahoo.com - July 2 at 6:40 AM |
| PTC Therapeutics, Inc. (PTCT) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 1 at 7:23 AM |
 | Company Spotlight: PTC Therapeutics
www.rttnews.com - July 1 at 6:44 AM |
| PTC Therapeutics' (PTCT) Neutral Rating Reiterated at J P Morgan Chase & Co
www.americanbankingnews.com - June 30 at 2:53 PM |
 | PTC Therapeutics: The Star Is Rising
seekingalpha.com - June 27 at 7:27 PM |
| PTC Therapeutics (PTCT) Announces New Analyses of Translarna Data from ACT DMD Presented at EPNS
www.streetinsider.com - June 23 at 8:05 PM |
| PTC Therapeutics (PTCT) Announces New Analyses of Translarna Data from ACT DMD Presented at EPNS - StreetInsider.com
www.streetinsider.com - June 23 at 9:18 AM |
| ETFs with exposure to PTC Therapeutics, Inc. : June 22, 2017
finance.yahoo.com - June 23 at 9:18 AM |
| New Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress
finance.yahoo.com - June 22 at 8:41 AM |
| PTC Therapeutics, Inc. (PTCT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - June 19 at 10:48 PM |
| ETFs with exposure to PTC Therapeutics, Inc. : June 12, 2017
finance.yahoo.com - June 12 at 6:59 PM |
| PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 3:46 PM |
| Today's Research Reports on Stocks to Watch: PTC Therapeutics and Organovo
finance.yahoo.com - June 8 at 8:58 AM |
| PTC Therapeutics, Inc. (PTCT) Receives Buy Rating from Citigroup Inc
www.americanbankingnews.com - June 7 at 12:22 PM |
| PTC Therapeutics Announces FDA Advisory Committee Meeting for Ataluren for the Treatment of Nonsense Mutation Dystrophinopathy
finance.yahoo.com - June 6 at 8:12 PM |
| PTC Therapeutics (PTCT) Names Marcio Souza Chief Operating Officer - StreetInsider.com
www.streetinsider.com - June 6 at 12:58 AM |
 | PTC Therapeutics Moves On Old Report - Benzinga
www.benzinga.com - June 1 at 8:34 PM |
| Dawn Svoronos Purchases 25,000 Shares of PTC Therapeutics, Inc. (PTCT) Stock
www.americanbankingnews.com - May 24 at 7:41 PM |
 | New Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics ... - PR Newswire (press release)
www.prnewswire.com - May 24 at 7:40 PM |
| PTC Therapeutics, Inc. (PTCT) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 23 at 8:22 PM |
| New Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting
finance.yahoo.com - May 23 at 9:46 AM |
| PTC Therapeutics, Inc. (PTCT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 11 at 8:24 AM |
| PTC Therapeutics, Inc. (PTCT) Given a $12.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - May 9 at 6:52 PM |
| Today's Research Reports on Stocks to Watch: Horizon Pharma and PTC Therapeutics
finance.yahoo.com - May 9 at 10:59 AM |
| PTC Therapeutics, Inc. (PTCT) Announces Quarterly Earnings Results, Beats Estimates By $0.18 EPS
www.americanbankingnews.com - May 8 at 8:16 PM |
| Why PTC Therapeutics Stock Is Sinking Today
finance.yahoo.com - May 8 at 6:43 PM |
| Investor Network: PTC Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 11:55 AM |
| PTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 8 at 11:55 AM |
| [$$] PTC Expects Net Price of $35,000 Annually Per Patient for Emflaza
finance.yahoo.com - May 8 at 11:55 AM |
| This rare disease drug’s price tag was reduced from $89,000-a-year. But that may not be enough
finance.yahoo.com - May 8 at 11:55 AM |
 | PTC Therapeutics reports 1Q loss
marketbeat.com - May 8 at 7:49 AM |
| 5 Stocks with Earnings Acceleration to Buy Now
finance.yahoo.com - May 2 at 5:11 PM |
| PTC Therapeutics (PTCT) Earning Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - May 2 at 11:40 AM |
| PTC Therapeutics, Inc. (PTCT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 29 at 1:22 AM |
| PTC Therapeutics (PTCT) Given News Sentiment Score of 0.20
www.americanbankingnews.com - April 27 at 10:38 PM |
| Somewhat Critical Press Coverage Likely to Affect PTC Therapeutics (PTCT) Share Price
www.americanbankingnews.com - April 24 at 6:28 PM |
| PTC Therapeutics (PTCT) Given Coverage Optimism Score of 0.04
www.americanbankingnews.com - April 22 at 12:59 AM |
| PTC Therapeutics, Inc. (PTCT) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 21 at 11:01 AM |
| PTC Therapeutics Completes Acquisition of Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in the U.S. - PR Newswire (press release)
www.prnewswire.com - April 21 at 8:48 AM |
PTC Therapeutics (PTCT) Chart for Monday, July, 24, 2017
